Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsPublished phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.
Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders
Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia
FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies
Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates
1.
Study sheds light on challenges for women of color after breast cancer surgery
2.
Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy
3.
FDA Approves CAR-T Product Use for Myeloma Early.
4.
How 7,000 steps a day could help reduce your risk of cancer
5.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
1.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
2.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
3.
Liquid Biopsies and ctDNA: Transforming Cancer Detection, Monitoring, and Clinical Decisions
4.
How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review
5.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Oropharyngeal Cancer in Relation to HPV Status
5.
Efficient Management of First line ALK-rearranged NSCLC - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge